FDA ap­proves Basilea’s an­tibi­ot­ic for se­vere bac­te­r­i­al in­fec­tions

The FDA on Wednes­day ap­proved Basilea’s an­tibi­ot­ic Zevtera to treat three con­di­tions: staph in­fec­tions, acute bac­te­r­i­al skin and skin struc­ture in­fec­tions, and com­mu­ni­ty-ac­quired bac­te­r­i­al pneu­mo­nia …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER